Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Trial of NP-178 (Emoxipin) for the Treatment of Inflammatory Bowel Disease

Trial Profile

A Phase IIa Trial of NP-178 (Emoxipin) for the Treatment of Inflammatory Bowel Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emoxipin (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2018 New trial record
    • 13 Nov 2018 According to a Nash Pharmaceuticals media release, the company plan to present preclinical in vivo IBD results at an upcoming conference and will update the market on plans for this phase IIa study for the leading repurposed IBD candidate NP-178 in 2019 pending additional results shortly.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top